Estradiol topical - Orion

Drug Profile

Estradiol topical - Orion

Alternative Names: Divigel; Estradiol gel - Orion; Estradiol hemihydrate; Gynpolar; Sandrena; Sisare Gel Mono

Latest Information Update: 27 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Orion
  • Developer Merck & Co; POLA PHARMA; Vertical Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Postmenopausal osteoporosis; Vasomotor symptoms

Most Recent Events

  • 24 Mar 2014 Vertical Pharmaceuticals acquires estradiol topical from Upsher-Smith in USA
  • 20 Aug 2013 Biomarkers information updated
  • 30 Jun 2009 Final efficacy and adverse events data from a phase III trial in Vasomotor symptoms released by Upsher-Smith Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top